The Operation That Shouldn't Still Be Happening
What a seven-minute procedure reveals about the real opportunity in women's health investing
Special note: My book The Billion Dollar Blindspot is available for pre-order on Amazon. It’s currently #3 on Amazon hot new releases in our category. Will you help me make it to #1?
This week on Signal Not Noise - Why Gilead paid $5 billion for a European biotech company and what this means for where capital moves next. If you advise private wealth clients or allocate institutional capital, Signal Not Noise is written for you — weekly capital intelligence on women's health investing, delivered directly to your inbox. 30% off through April.
It takes seven minutes.
No operating theatre. No anesthesia. No machines humming in the background. A woman walks into a doctor’s office, lies back, and in less time than it takes to answer a few emails, a procedure is done that could change the trajectory of her life. Then she stands up, gets dressed, and drives herself home.
Nothing about it looks like a revolution. And that is precisely the point.
For decades, heavy menstrual bleeding has been treated as something to manage rather than something to solve. The language around it has always carried a quiet resignation: it’s common, it’s normal, let’s try something conservative first. Beneath those phrases sits an unspoken hierarchy of urgency. Conditions that affect women — especially those tied to reproductive health — have been systematically deprioritised because they have been culturally and clinically normalised.
The pathway reflects that thinking. Medication first. Hormonal interventions. Devices. Months, sometimes years, of trial and error. And if none of it works, escalation to surgery, and often a hysterectomy for what is, in many cases, a benign condition. A permanent solution at the end of a long corridor of compromise.
Tara Murphy of Cerene describes a technology that disrupts that entire pathway by removing complexity. The procedure can be performed in a physician’s office, requires no anesthesia, no capital equipment, and takes minutes. It is designed to fit into real clinical workflows rather than forcing systems to adapt around it.
That distinction matters more than it appears. In healthcare, adoption is rarely determined by innovation alone. It is determined by friction.
How easy is it for a physician to learn?
How seamlessly does it integrate into existing practice?
How quickly can a patient access it?
Every additional layer, equipment, training, reimbursement uncertainty, slows the system down. And in women’s health, where delays are already normalised, that friction compounds.
What Cerene represents is not just a new treatment. It is a re-engineering of access.
But this is not the first time the market has seen a signal like this. Tara’s previous experience at Gynesonics provides an important proof point. With the right technology, team, and execution, women’s health innovations can deliver both clinical impact and investor returns. The demand was never the issue. The constraint was structural with the most significant of those constraints being reimbursement.
When more than half of eligible patients are denied coverage in the early years of commercialisation of a new women’s health tech, it isn’t the science that’s faltering. It is the infrastructure around it. Those lessons have been absorbed into how Cerene was built.
One of the most overlooked elements of that strategy is how companies communicate with women themselves. In many areas of medicine, the physician is the gatekeeper.
In women’s health, the patient often plays a far more active role and if she does not know that a treatment exists, she cannot ask for it. Advocacy groups and patient networks have become a critical layer in the ecosystem for precisely this reason: they are not simply raising awareness, they are accelerating adoption, connecting patients to providers, and helping redefine what is considered standard of care. In a category where historical underinvestment has left gaps not just in treatment but in knowledge, these networks function as a form of distribution.
Seen through that lens, scaling a women’s health company is not just a matter of clinical validation or regulatory approval. It is about aligning multiple systems at once: clinical practice, reimbursement structures, and patient awareness. When those systems move together, adoption can happen far more quickly than most investor models expect and the returns follow the same logic.
Cerene enters the market at a moment when many of these pieces are already in place. The lessons from earlier companies have been absorbed. Reimbursement pathways are clearer. The technology itself has been designed to minimise friction. And the conversation around women’s health is beginning to shift not from neglect to advocacy, but from neglect to opportunity. Those are different destinations, and the capital implications of that shift have not yet been fully priced in.
Still, the most powerful aspect of this story is how unremarkable it looks on the surface. Seven minutes. No anesthesia. No equipment.
It does not resemble the kind of breakthrough that typically captures attention. There is no dramatic new molecule, no complex machine, no headline-grabbing innovation. And yet it is precisely this kind of system-aware, friction-removing improvement that has the potential to drive the most meaningful change and, for investors paying attention, the most durable returns.
Because healthcare systems do not transform overnight. They shift when something becomes easier. Faster. More accessible. When the default changes.
For decades, the default in women’s health has been delay; delay in diagnosis, delay in treatment, delay in capital. That delay has carried enormous costs, both human and economic. What companies like Cerene are beginning to show is that when you remove enough friction, the system moves. And when the system moves, the question is no longer whether the market will follow.
On 28 May, I’m hosting a private conversation with some of the people who have lived this arc; operators who have built and exited in women’s health, and an investor who has backed multiple companies in the space. We will be talking about what it actually takes to build in this category, what the reimbursement and adoption curve looks like from the inside, and where the capital opportunity sits right now.
It is not a panel. It is a practitioner conversation and the kind that usually happens behind closed doors. If you want to be in the room, you can request an invitation below.
Three years ago, I started writing what I thought was a report. It became a book. Today, The Billion Dollar Blindspot is available for pre-order.
Disclaimer & Disclosure
This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.